Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Non-radiographic axial spondyloarthritis (nr-axSpA) is an early stage of axial spondyloarthritis characterized by the absence of definitive radiographic changes. Interleukin-17 inhibitors (IL-17i) have shown efficacy in treating nr-axSpA, but a significant proportion of patients fail to respond. Identifying predictive biomarkers for IL-17i response is crucial for optimizing treatment strategies.
Methods: This retrospective study analyzed pre-treatment serum samples from nr-axSpA patients treated with secukinumab. Responders (R) and non-responders (NR) were defined based on changes in ASDAS-CRP scores after 12 weeks of therapy. Serum protein profiles were analyzed using liquid chromatography-tandem mass spectrometry (LC-MS/MS) with label-free quantification, followed by validation of candidate proteins using enzyme-linked immunosorbent assay (ELISA). Statistical analyses included Student's t-test, Mann-Whitney U-test, and Spearman's correlation.
Results: LC-MS/MS identified 47 differentially expressed proteins (DEPs) between R and NR groups, with 31 upregulated and 16 downregulated in NR. Seven proteins including heat shock protein HSP 90-alpha (HSP90α) and serotransferrin were selected for ELISA validation. ELISA confirmed significantly higher HSP90α (p = 0.027) and lower serotransferrin (p = 0.034) levels in NR compared to R. HSP90α showed a mild negative correlation with the reduction of BASDAI scores (r = -0.30, p = 0.035), while serotransferrin exhibited a mild positive correlation (r = 0.287, p = 0.048). Both proteins correlate mildly with the disease activity index.
Conclusion: Serum levels of HSP90α and serotransferrin may serve as potential biomarkers for predicting IL-17i treatment response in nr-axSpA patients. Elevated HSP90α and reduced serotransferrin levels may reflect chronic inflammation and disease activity, particularly from a subjective symptom perspective. Further validation in prospective studies is needed to confirm their utility in guiding personalized treatment strategies.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/1756-185X.70303 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effectiveness of a checklist for the control of the disease activity in patients with axial spondyloarthritis.
Reumatol Clin (Engl Ed)
September 2025
Hospital Universitario Fundación Alcorcón, Unit of Rheumatology, Madrid, Spain.
Objectives: To assess the effectiveness of a checklist for disease activity and comorbidity control in patients with axial spondyloarthritis (axSpA).
Method: A quasi-experimental retrospective multicentre pre-post intervention study was carried out in Spain between 2016 and 2022. Improvement in disease activity and comorbidity status was determined before and after the implementation of a checklist control in patients diagnosed with axSpA.
ASAS recommendations on reporting axial spondyloarthritis clinical trials.
Ann Rheum Dis
September 2025
Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands.
Objectives: This study aims to develop recommendations on reporting baseline features and outcomes from axial spondyloarthritis (axSpA) clinical trials based on the recently updated instrument set of the Assessment of SpondyloArthritis international Society (ASAS) core outcome set (COS).
Methods: A steering group (SG) convened a workgroup (WG), consisting of 13 ASAS members including rheumatologists, methodologists, epidemiologists, and 2 Young ASAS members. Recommendations on reporting axSpA trials baseline features and outcomes were developed in 3 steps: (1) the SG identified relevant baseline features from key axSpA clinical trials and formulated a proposal on how outcomes related to the instruments in the ASAS COS should be presented.
Entheseal structural damage according to OMERACT definitions unveils distinct ultrasound phenotypes in SpA: findings from the DEUS multicentre study.
Semin Arthritis Rheum
August 2025
Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK; Rheumatology Unit, Department of Clinical and Molecular Sciences, "Carlo Urbani" Hospital, Polytechnic University of Marche, Ancona, Italy. Electronic address:
Objectives: To explore the prevalence and distribution of ultrasound-detected lesions indicating structural damage at the enthesis (e.g., bone erosions, enthesophytes, and calcifications) in patients with spondyloarthritis (SpA), comparing those with axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA), and to investigate the demographic, clinical, and metabolic factors linked to these lesions.
View Article and Find Full Text PDFPrevalence of sacroiliitis on magnetic resonance enterography in Crohn's disease and its association with intestinal findings: a monocentric observational cross-sectional study.
Clin Exp Med
September 2025
Chair of Rheumatology, University Hospital of Modena, University of Modena and Reggio Emilia, Policlinico Di Modena, Via del Pozzo, 71, 41125, Modena, Italy.
Magnetic resonance enterography (MRE) is recommended for the assessment of small intestine alterations in Crohn's disease (CD). Sacroiliac joints (SIJs) imaging has a central role in the early diagnosis of sacroiliitis (SI). MRE can evaluate both acute and structural findings of SIJs.
View Article and Find Full Text PDFEarly diagnosis of axial spondyloarthritis among patients with chronic back pain using a clinical screening tool and referral strategy.
Rheumatol Adv Pract
July 2025
Department of Medicine, Yale School of Medicine, New Haven, CT, USA.
Objective: Lack of timely referral of suspected axial spondyloarthritis (axSpA) patients to rheumatologists is an important modifiable reason for diagnostic delay of axSpA. We assessed the usefulness of a self-referral strategy using a clinical feature-based screening questionnaire (SQ) (A-tool).
Methods: Finding axSpA (FaxSpA) was single-centre prospective study involving patients with chronic back pain (CBP).